The Latest Breaking News from Hims Hers Health

Hims stock toppled Tuesday after the FDA issued the telehealth giant a warning letter regarding its knockoff version of semaglutide.

Hims Hers Health Inc. (NYSE:HIMS) launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

Hims Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three…

The major indexes ended the session in negative territory Tuesday.

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Shares of telehealth company Hims Hers Health Inc (NYSE:HIMS) are up Thursday afternoon, and at one point, approached a new all-time high. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.

Hims stock is climbing back from a steep drop within a base. Shares have climbed nearly 29% during the month and outperformed 98% of stocks.

Hims Hers Health, Inc. (NYSE:HIMS) has seen a surge in retail investor interest, which positions it as one of the most high-profile candidates for the next “meme stock” rally. 

Hims Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.